Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. J.P. Morgan Cuts Price Target on Acorda (ACOR) Stock ... Sep 10, 2018 · Did an iceberg just wallop into Acorda (ACOR) stock? The drug maker's shares are plunging at breakneck speed of almost 22% after the U.S. Court of Appeals ACOR Acorda Therapeutics, Inc. Stock Quote Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Acorda Therapeutics (NASDAQ:ACOR) Stock Rating Lowered by ...
Based on analysts offering 12 month price targets for ACOR in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. Sign in to your
Acorda Therapeutics Inc (NASDAQ:ACOR) price target set to ... Analyst Ratings For Acorda Therapeutics Inc (NASDAQ:ACOR) Today, HC Wainwright set its price target on Acorda Therapeutics Inc (NASDAQ:ACOR) to $28.00 per share. There are 9 Hold Ratings, 3 Buy Acorda Therapeutics (ACOR) stock price is valued at $1.11 ... 12 days ago · Investors tracking shares of Acorda Therapeutics (ACOR) may be focusing on where the stock is trading relative to its 52-week high and low. At the time of writing, the stock had recently reached at $1.11. At this price, shares can be seen trading -91.80% off of the 52-week high mark and 58.55% away from the 52-week low. Acorda Therapeutics (ACOR) Stock in the Investors Queue ... Mar 16, 2020 · Many individual analysts and firms give their ratings on a stock. While Looking ahead of 52-week period, the mean Target Price set by analysts is $3.75. Now entering into the performance part of the article on Acorda Therapeutics stock we should check the stock’s actual performance in the past. Performance of the ACOR Stock:
23 May 2019 Below you'll find the most recent moves that we have seen from analysts as it relates to ACOR. Stop wasting your time! Start finding winning
Nov 08, 2019 · Acorda Therapeutics Inc. analyst estimates by MarketWatch. View ACOR revenue estimates and earnings estimates, as well as analyst recommendations. ACOR Stock Price, Forecast & News (Acorda Therapeutics) Here are some recent quotes from research analysts about Acorda Therapeutics stock: 1. Stifel Nicolaus analysts commented, "Stifel analyst Paul Matteis lowered the price target on Acorda Therapeutics, Inc. (NASDAQ: ACOR) to $7.00 (from $12.00) while maintaining a Hold rating." (8/2/2019) 2. ACOR Price Target and Analyst Ratings (Acorda Therapeutics) Nov 08, 2019 · 6 Wall Street analysts have issued ratings and price targets for Acorda Therapeutics in the last 12 months. Their average twelve-month price target is $7.23, suggesting that the stock has a possible upside of 805.41%. The high price target for ACOR is …
The median ACOR price target (a different metric than the average or mean) was $ as of , the highest ACOR price target in the range was $ while the lowest ACOR price target in the range was $, with a standard deviation of $. Get the latest Zacks research report on ACOR — FREE. 10 ETFs With Most Upside To Analyst Targets
Acorda Therapeutics (ACOR) Stock in the Investors Queue ... Mar 16, 2020 · Many individual analysts and firms give their ratings on a stock. While Looking ahead of 52-week period, the mean Target Price set by analysts is $3.75. Now entering into the performance part of the article on Acorda Therapeutics stock we should check the stock’s actual performance in the past. Performance of the ACOR Stock: Acorda Therapeutics, Inc. (ACOR) stock price, quote ... Acorda Therapeutics to Present at Cowen Annual Health Care Conference. Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda’s President and Chief Executive Officer, will present at the Cowen and Company Annual Health Care Conference on Monday, March 2 at 2:50PM EST. Acorda Therapeutics (NASDAQ:ACOR) Upgraded to Buy at ... ValuEngine upgraded shares of Acorda Therapeutics (NASDAQ:ACOR) from a hold rating to a buy rating in a research report sent to investors on Thursday morning, ValuEngine reports. Several other equities research analysts also recently commented on ACOR. Cowen reaffirmed a buy rating and issued a $10.00 target price on shares of Acorda Therapeutics in a […]
Acorda Therapeutics started at neutral with $12 stock price target at Wedbush May. 23, 2019 at 7:35 a.m. ET by Tomi Kilgore Acorda Therapeutics stock price target cut to $15 from $18 at Oppenheimer
Acorda Therapeutics gained 3.28% in the last trading day ( Friday, 3rd Apr 2020 ), rising from $0.85 to $0.87, and has now gained 3 days in a row.It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the day the stock fluctuated 8.91% from a day low at $0.82 to a day high of $0.89.The price has been going up and down for this ACOR Acorda Therapeutics, Inc. — Stock Price and ... Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures. Acorda Therapeutics, Inc. Common Stock (ACOR) Stock Quotes ...